BSEBoard Meeting22 Oct 2026 · 22 Oct 2026, 02:47 pm

Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve Standalone and Consolidated Unaudited Financial Results of the Company for the Quarter and Half year ended 30.09.2026.

Lincoln Pharmaceuticals Ltd · 531633

✦ AI SummaryResults

Lincoln Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 29/10/2026 to consider and approve Standalone and Consolidated Unaudited Financial Results for the Quarter and Half year ended 30.09.2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Lincoln Pharmaceuticals Ltd - 531633 - Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter And Half Year Ended 30.09.2026.

Attachments (1)

📄

b1b301cf-ac1e-448b-af74-d7f8df4680ba.pdf

pdf

Download →
View document text
LINCOLN PHARMACEUTICALS LTD. HEALTHCARE FOR ALL Date: 22nd October, 2026 To, To, The Manager, Listing Department, The Department of Corporate Service, National Stock Exchange of India Limited BSE Limited, (NSE), 1st Floor, New Trading Ring, Rotunda Building, Exchange Plaza, C – 1, Block – G, Bandra – Phiroze Jeejeebhoy Tower, Dalal Street, Kurla Complex, Bandra (E), Mumbai-400 051. Mumbai – 400 001. Scrip Code-LINCOLN Scrip Code-531633 Dear Sir / Madam, Sub.: Intimation of Board Meeting. Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Meeting of the Board of Directors of the Company is scheduled to be held on Thursday, 29th October, 2026 for considering inter-alia the following matters:- 1) To consider and approve un-audited financial results (standalone and consolidated) of the Company for the quarter and half year ended on September 30, 2026; 2) Any other business with the permission of the Chairman, if any. Pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, trading window has been closed for trading in securities of the Company from October 01, 2026 and shall reopen after the expiry of 48 hours from the time the result becomes generally available. Kindly take the same on record. Thanking you, Yours faithfully, For Lincoln Pharmaceuticals Limited Trusha Shah Company Secretary & Compliance Officer Regd. Office: "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India "i® Phone, +91-79-4107 8000 I Fax, +91-79-4107 8062 I CIN L24230GJ1995PLC024288 E-mail: info@lincolnpharma.com l Website: www.lincolnpharma.com Factory: 10, 12, 13. Trimul Estate. Near Khatraj Chokadi, P.O. Khatraj-382721. Ta.: Kalal, Dist. Gandhinagar, (Guj.) I Phone: +91-79-49135000 I E-mail: khatraj@lincolnpharma.com .,,. lntertek '"